Advanced Renal Cell Carcinoma: Clinical Practice Pearls
Drs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.
Role of Community and Academic Centers in the Treatment of Patients with Advanced RCC
Dr Sumeet Bhatia highlights the challenges faced by community oncologists who treat patients with advanced renal cell carcinoma and which patients they refer to academic centers.
Toxicities and Quality of Life with IO-IO Therapies in Patients with Advanced RCC
Two oncologists describe common adverse events seen with IO-IO combination treatment regimens for advanced renal cell carcinoma, and how they interpret quality of life data from the CheckMate 214 trial.
Advanced Renal Cell Carcinoma and Brain Metastases
Experts discuss how to treat advanced renal cell carcinoma with brain metastases and when to refer patients to an academic center.
Nivolumab + Ipilimumab Therapy as Frontline Therapy for Advanced Renal Cell Carcinoma
Treating a patient with advanced renal cell carcinoma with ipilimumab-nivolumab based on data from the CheckMate 214 trial.
Patient Profile Presentation: A 41-Year-Old Male with Advanced Renal Cell Carcinoma
Sumeet Bhatia, MD, presents the patient profile of a 47-year-old male patient with advanced renal cell carcinoma.
Impact of Adjuvant Pembrolizumab Approval on RCC Treatment Landscape
Two key opinion leaders review data from a phase 3 clinical trial assessing the use of lenvatinib plus pembrolizumab for the treatment of advanced renal cell carcinoma.
Adverse Events with IO-TKI Combination Treatment Regimens
Two oncologists describe common adverse events seen with I/O–TKI combination treatment regimens for advanced renal cell carcinoma and when they choose to stop the therapy.
Lenvatinib + Pembrolizumab as Frontline Therapy for Advanced Renal Cell Carcinoma
Dr Eric Jonasch discusses why he chose to treat his patient’s advanced renal cell carcinoma with lenvatinib-pembrolizumab and how he modifies the dosage throughout treatment.
Considerations for Treatment Decision Making for Advanced Renal Cell Carcinoma
Sumeet Bhatia, MD, explains the factors he considers in choosing a treatment for advanced renal cell carcinoma and the role biomarkers have in the process.
Patient Profile Presentation: A 61-Year-Old Man with Advanced Renal Cell Carcinoma
Eric Jonasch, MD, presents a real world advanced renal cell carcinoma patient profile and reviews the available first-line IO-TKI combination treatment regimens.
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL
Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma
Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL
2 Clarke Drive Cranbury, NJ 08512